HeartSciences Inc. (NASDAQ:HSCS – Get Free Report)’s share price passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $2.72 and traded as high as $3.07. HeartSciences shares last traded at $2.83, with a volume of 76,630 shares.
Wall Street Analyst Weigh In
A number of analysts have commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a report on Monday, September 21st. Wall Street Zen raised shares of HeartSciences from a “sell” rating to a “hold” rating in a research note on Sunday, September 20th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, HeartSciences has an average rating of “Hold” and a consensus target price of $8.00.
Get Our Latest Stock Report on HeartSciences
HeartSciences Stock Performance
The firm has a fifty day simple moving average of $3.60 and a 200 day simple moving average of $2.72. The company has a market capitalization of $14.07 million, a PE ratio of -0.88 and a beta of 1.80.
HeartSciences (NASDAQ:HSCS – Get Free Report) last announced its quarterly earnings results on Monday, September 14th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.14). The firm had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.10 million. Research analysts expect that HeartSciences Inc. will post -2.99 EPS for the current fiscal year.
About HeartSciences
HeartSciences, Inc (NASDAQ: HSCS) is a medical technology company focused on improving the detection and assessment of heart disease through advanced electrocardiography (ECG). The company develops diagnostic tools designed to provide clinicians with additional information about cardiac function using a standard, noninvasive ECG test.
Its principal technology is the MyoVista ECG system, which uses the company’s proprietary wavelet-based ECG, or wavECG, technology. MyoVista is designed to assess mechanical aspects of the heart, including left ventricular diastolic function, which may help identify cardiac abnormalities that are not readily detected through conventional ECG analysis.
Further Reading
- Five stocks we like better than HeartSciences
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for HeartSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartSciences and related companies with MarketBeat.com's FREE daily email newsletter.
